Scholar Rock Corp (SRRK) - שולי הרווח הגולמי

סמלים רשמיים של חברת Scholar Rock Corp (SRRK)

The development of innovative treatments for fibrosis and muscle atrophy is driving growth for Scholar Rock (SRRK), although the gross margin as a percentage of revenue exhibits volatility. This is due to the biotech sector's lack of cyclical economic dependence and future monopoly pricing power for unique medications. The value of -132.10 serves as the baseline parameter, capturing the company's actual operational state without market noise.

SRRK שולי רווח גולמי Scholar Rock Holding Corporation (04.07.2022 - 20.11.2026)

פילוחים אנליטיים ודוחות נתונים של חברת Scholar Rock, Inc. (SRRK)

- מחיר שוק ויעדי מחיר של אנליסטים:
ניתוח בסיסי של החברה:Scholar Rock Holding Corporation, SRRK
מוצרים מיוצרים של Scholar Rock Holding Corporation

Geopolitical instability and the disruption of reagent supply chains for neuromuscular disease therapies directly increase the development costs for Scholar Rock (SRRK). The ratio of gross profit to revenue, reflected in the quarterly gross margin, measures production efficiency; an increase in this ratio confirms cost optimization, while extreme values signal the risk of overpaying for the asset.